Associated Papers
ATM deficiency confers specific therapeutic vulnerabilities in bladder cancer.
Zhou Y et al.
Science Advances, 2023
37992168 (PubMed )
Supplement: sciadv.adg2263_tables_s1_to_s5.zip › adg2263_Table_S1.xlsx › Genomic_data
Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas.
Berrino E et al.
Genome Medicine, 2022
36038884 (PubMed )
Supplement: 13073_2022_1104_MOESM10_ESM.xlsx › Supplementary_Table_S5
Validation of a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNA.
Finkle JD et al.
Npj Precision Oncology, 2021
34215841 (PubMed )
Supplement: 41698_2021_202_MOESM1_ESM.pdf
Comprehensive omic characterization of breast cancer in Mexican-Hispanic women.
Romero-Cordoba SL et al.
Nature Communications, 2021
33854067 (PubMed )
Supplement: 41467_2021_22478_MOESM9_ESM.xlsx › Driver_mutation_in_HM
A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma.
Nassar AH et al.
British Journal of Cancer, 2020
31857723 (PubMed )
Supplement: 41416_2019_686_MOESM1_ESM.xlsx › S1.2_Overall_SNV_small_indels
Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites.
Nassar AH et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2019
30593515 (PubMed )
Supplement: 10780432ccr183147-sup-209386_2_supp_5192871_ptz639.xlsx › S1.3_Raw_SNV_and_small_indels
Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer.
Liu D et al.
Nature Communications, 2017
29259186 (PubMed )
Supplement: 41467_2017_2320_MOESM1_ESM.pdf
Select a paper to view details